GAG-PEmax V7
(Plasmid
#232921)
-
PurposeOptimized construct for the expression of PEmax fused to GAG from fMLV. This plasmid is involved in the production of NanoScribes
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 232921 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepCDNA3-like
- Total vector size (bp) 12313
-
Vector typeMammalian Expression, CRISPR
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameGAG FMLV fused to PEmax
-
Alt nameEditor V7
-
SpeciesH. sapiens (human), M. musculus (mouse)
-
Insert Size (bp)5877
-
Tag
/ Fusion Protein
- Nuclear export signals (x3) (C terminal on insert)
Resource Information
-
A portion of this plasmid was derived from a plasmid made byPhilippe Mangeot, Théophile Ohlmann and Emiliano Ricci (backbone derived from BIC-CAS9; Addgene #119942), and David Liu (PEmax amplified from Addgene #174820).
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
Addgene observed 1 base pair mismatch in the ORF leading to H102Y substitution. This discrepancy was found to not affect plasmid function.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
GAG-PEmax V7 was a gift from Philippe Mangeot (Addgene plasmid # 232921 ; http://n2t.net/addgene:232921 ; RRID:Addgene_232921) -
For your References section:
Delivery of Prime editing in human stem cells using pseudoviral NanoScribes particles. Halegua T, Risson V, Carras J, Rouyer M, Coudert L, Jacquier A, Schaeffer L, Ohlmann T, Mangeot PE. Nat Commun. 2025 Jan 4;16(1):397. doi: 10.1038/s41467-024-55604-0. 10.1038/s41467-024-55604-0 PubMed 39755699